MaxCyte
MXCT
108 hedge funds and large institutions have $452M invested in MaxCyte in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
41% more capital invested
Capital invested by funds: $321M → $452M (+$131M)
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6% more funds holding
Funds holding: 102 → 108 (+6)
1.44% more ownership
Funds ownership: 66.98% → 68.42% (+1.4%)
Top Buyers
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$18M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.08M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.43M |
| 4 |
BlackRock
New York
|
+$4.38M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$3.9M |
Top Sellers
| 1 |
CC
Casdin Capital
New York
|
-$18M |
| 2 |
Millennium Management
New York
|
-$5.19M |
| 3 |
Goldman Sachs
New York
|
-$4.65M |
| 4 |
RI
RTW Investments
New York
|
-$3.65M |
| 5 |
Citigroup
New York
|
-$2.94M |
MXCT Hedge Fund Activity: Q3 2022 in Review
108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q3 2022, worth a combined $452M — up 41% from $321M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MXCT positions and 11 closed out — a net gain of 7 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $18M. The largest seller was Casdin Capital, cutting an estimated $18M.
- 108 institutional investors held MaxCyte (MXCT) as of Q3 2022, up from 102 in Q2 2022.
- Funds reported $452M of MaxCyte stock for Q3 2022, up 41% quarter-over-quarter.
- 18 funds opened new MaxCyte positions in Q3 2022 and 11 closed out, a net change of +7 holders.
- The largest MaxCyte buyer in Q3 2022 was Blue Water Life Science Advisors, an estimated $18M added.
- The largest MaxCyte seller in Q3 2022 was Casdin Capital, an estimated $18M sold.
Based on aggregated 13F filings for Q3 2022.